Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. is positioned positively due to its innovative approach in developing programmed cellular immunotherapies using induced pluripotent stem cell (iPSC) technology, which addresses significant challenges in the sector, including cost-effective manufacturing and the off-the-shelf availability of treatments. Early clinical results, particularly from the allogeneic CAR-T product candidate FT819, have shown promising efficacy in heavily pretreated systemic lupus erythematosus (SLE) patients, indicating the potential for durable therapeutic improvements. Additionally, the positive findings presented at recent medical conferences bolster the company's credibility as a leader in the field, reinforcing a favorable outlook for its future in the biopharmaceutical market.

Bears say

Fate Therapeutics Inc faces several significant risks that contribute to a negative outlook on its stock, including the potential failure to demonstrate a clinical efficacy advantage of its FT819 product compared to existing CAR-T therapies. Concerns regarding safety, immunogenicity, and regulatory backlash, alongside risks related to partnerships, may negatively impact the company's future growth and viability. Additionally, the observed transient nature of B-cell depletion in early trials raises further doubts about the long-term effectiveness and durability of treatment outcomes within its immunotherapy pipeline.

Fate Therapeutics (FATE) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 6 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.